Matrix metalloproteinases in respiratory diseases: From pathogenesis to potential clinical implications

Current Medicinal Chemistry

Volumn 16, Issue 10, 2009, Pages 1214-1228

  Oikonomidi, Smaragda ^a   Kostikas, Konstantinos ^a   Tsilioni, Irene ^a   Tanou, Kalliopi ^a   Gourgoulianis, Konstantinos I ^a   Kiropoulos, Theodoros S ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Extracellular matrix; Lung cancer; Matrix metalloproteinases; Pleural effusions

Indexed keywords

BATIMASTAT; CARBOPLATIN; COLLAGEN; COLLAGENASE 3; CORTICOSTEROID; DEXAMETHASONE; FIBRONECTIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; PACLITAXEL; PLACEBO; PRINOMASTAT; PROTEOGLYCAN; REBIMASTAT; RS 113456; STROMELYSIN; STROMELYSIN 2; SUCCINATE PEPTIDOMIMETIC INHIBITOR; SULFONAMIDE INHIBITOR; TANOMASTAT; THIOL REAGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ASCITES; ASTHMA; BASEMENT MEMBRANE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; EMPHYSEMA; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG CANCER; LUNG DISEASE; LUNG NON SMALL CELL CANCER; LUNG SARCOIDOSIS; LUNG SMALL CELL CANCER; NAUSEA AND VOMITING; NONHUMAN; PATHOGENESIS; PLEURA EFFUSION; PLEURODESIS; PROTEIN EXPRESSION; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFLAMMATION; REVIEW; UNSPECIFIED SIDE EFFECT;

HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASES; PLEURAL EFFUSION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 65649096201     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787846587     Document Type: Review

References (209)

1. Sternlicht, M.D.; Werb, Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol., 2001, 17, 463-516.
2. Gross, J.; Lapiere, C.M. Collagenolytic activity in amphibian tissues: A tissue culture assay. Proc. Natl. Acad. Sci. USA, 1962, 48, 1014-22.
3. Mandal, M.; Mandal, A.; Das, S.; Chakraborti, T.; Sajal, C. Clinical implications of matrix metalloproteinases. Mol. Cell Biochem., 2003, 252, 305-29.
4. Massova, I.; Kotra, L.P.; Fridman, R.; Mobashery, S. Matrix metalloproteinases: Structures, evolution, and diversification. FASEB J., 1998, 12, 1075-95.
5. Dunsmore, S.E.; Rannels, D.E. Extracellular matrix biology in the lung. Am. J. Physiol., 1996, 270, L3-27.
6. Mott, J.D.; Werb, Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol., 2004, 16, 558-64.
7. Schnaper, H.W.; Kleinman, H.K. Regulation of cell function by extracellular matrix. Pediatr. Nephrol., 1993, 7, 96-104.
8. von der Mark, K.; von der Mark, H.; Goodman, S. Cellular responses to extracellular matrix. Kidney Int., 1992, 41, 632-40.
9. Adams, J.C.; Watt, F.M. Regulation of development and differentiation by the extracellular matrix. Development, 1993, 117, 1183-98.
10. Damsky, C.; Sutherland, A.; Fisher, S. Extracellular matrix 5: Adhesive interactions in early mammalian embryogenesis, implantation, and placentation. FASEB J., 1993, 7, 1320-29.
11. Gailit, J.; Clark, R.A. Wound repair in the context of extracellular matrix. Curr. Opin. Cell Biol., 1994, 6, 717-25.
12. Raghow, R. The role of extracellular matrix in postinflammatory wound healing and fibrosis. FASEB J., 1994, 8, 823-31.
13. Stetler-Stevenson, W.G.; Aznavoorian, S.; Liotta, L.A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol., 1993, 9, 541-73.
14. Stracke, M.L.; Murata, J.; Aznavoorian, S.; Liotta, L.A. The role of the extracellular matrix in tumor cell metastasis. In vivo, 1994, 8, 49-58.
15. Ingber, D. Extracellular matrix and cell shape: Potential control points for inhibition of angiogenesis. J. Cell Biochem., 1991, 47, 236-41.
16. Ingber, D.E. Extracellular matrix as a solid-state regulator in angiogenesis: Identification of new targets for anti-cancer therapy. Semin. Cancer Biol., 1992, 3, 57-63.
17. Davidson, J.M. Biochemistry and turnover of lung interstitium. Eur. Respir. J., 1990, 3, 1048-63.
18. Laurent, G.J. Dynamic state of collagen: Pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am. J. Physiol., 1987, 252, C1-9.
19. Laurent, G.J.; Harrison, N.K.; McAnulty, R.J. The regulation of collagen production in normal lung and during interstitial lung disease. Postgrad. Med. J., 1988, 64 Suppl. 4, 26-34.
20. Palmgren, M.S.; deShazo, R.D.; Carter, R.M.; Zimny, M.L.; Shah, S.V. Mechanisms of neutrophil damage to human alveolar extracellular matrix: the role of serine and metalloproteases. J. Allergy Clin. Immunol., 1992, 89, 905-15.
21. Campbell, E.J.; Senior, R.M.; Welgus, H.G. Extracellular matrix injury during lung inflammation. Chest, 1987, 92, 161-67.
22. Dunsmore, S.E.; Rannels, D.E. Turnover of extracellular matrix by type II pulmonary epithelial cells. Am. J. Physiol., 1995, 268, L336-46.
23. Rannels, D.E.; Dunsmore, S.E.; Grove, R.N. Extracellular matrix synthesis and turnover by type II pulmonary epithelial cells. Am. J. Physiol., 1992, 262, L582-89.
24. Ishii, Y.; Hashizume, Y.; Kominami, E.; Uchiyama, Y. Changes in immunoreactivity for cathepsin H in rat type II alveolar epithelial cells and its proteolytic activity in bronchoalveolar lavage fluid over 24 hours. Anat. Rec., 1991, 230, 519-23.
25. Funkhouser, J.D.; Tangada, S.D.; Jones, M.; O, S.J.; Peterson, R.D. p146 type II alveolar epithelial cell antigen is identical to aminopeptidase N. Am. J. Physiol., 1991, 260, L274-79.
26. Hook, G.E. Extracellular hydrolases of the lung. Biochemistry, 1978, 17, 520-28.
27. Spicer, S.S.; Frayser, R.; Virella, G.; Hall, B.J. Immunocytochemical localization of lysozymes in respiratory and other tissues. Lab. Invest., 1977, 36, 282-95.
28. Birkedal-Hansen, H.; Moore, W.G.; Bodden, M.K.; Windsor, L.J.; Birkedal-Hansen, B.; DeCarlo, A.; Engler, J.A. Matrix metalloproteinases: A review. Crit. Rev. Oral Biol. Med., 1993, 4, 197-250.
29. Ohbayashi, H. Matrix metalloproteinases in lung diseases. Curr. Protein Pept. Sci., 2002, 3, 409-21.
30. Roy, R.; Zhang, B.; Moses, M.A. Making the cut: Protease-mediated regulation of angiogenesis. Exp. Cell Res., 2006, 312, 608-22.
31. Kontogiorgis, C.A.; Papaioannou, P.; Hadjipavlou-Litina, D.J. Matrix metalloproteinase inhibitors: A review on pharmacophore mapping and (Q)SARs results. Curr. Med. Chem., 2005, 12, 339-55.
32. Lemaitre, V.; D'Armiento, J. Matrix metalloproteinases in development and disease. Birth. Defects Res. C. Embryo Today, 2006, 78, 1-10.
33. Skiles, J.W.; Gonnella, N.C.; Jeng, A.Y. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem., 2001, 8, 425-74.
34. Skiles, J.W.; Gonnella, N.C.; Jeng, A.Y. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr. Med. Chem., 2004, 11, 2911-77.
35. Vu, T.H.; Werb, Z. Matrix metalloproteinases: Effectors of development and normal physiology. Genes Dev., 2000, 14, 2123-33.
36. Haas, T.L.; Stitelman, D.; Davis, S.J.; Apte, S.S.; Madri, J.A. Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium. J. Biol. Chem., 1999, 274, 22679-85.
37. Han, X.; Boyd, P.J.; Colgan, S.; Madri, J.A.; Haas, T.L. Transcriptional up-regulation of endothelial cell matrix metalloproteinase-2 in response to extracellular cues involves GATA-2. J. Biol. Chem., 2003, 278, 47785-91.
38. Choi, J.; Choi, K.; Benveniste, E.N.; Rho, S.B.; Hong, Y.S.; Lee, J.H.; Kim, J.; Park, K. Bcl-2 promotes invasion and lung metastasis by inducing matrix metalloproteinase-2. Cancer Res., 2005, 65, 5554-60.
39. Lian, X.; Qin, Y.; Hossain, S.A.; Yang, L.; White, A.; Xu, H.; Shipley, J.M.; Li, T.; Senior, R.M.; Du, H.; Yan, C. Overexpression of Stat3C in pulmonary epithelium protects against hyperoxic lung injury. J. Immunol., 2005, 174, 7250-56.
40. Kheradmand, F.; Rishi, K.; Werb, Z. Signaling through the EGF receptor controls lung morphogenesis in part by regulating MT1-MMP-mediated activation of gelatinase A/MMP2. J. Cell Sci., 2002, 115, 839-48.
41. Cox, G.; Jones, J.L.; O'Byrne, K.J. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin. Cancer Res., 2000, 6, 2349-55.
42. Kang, H.R.; Cho, S.J.; Lee, C.G.; Homer, R.J.; Elias, J.A. Transforming growth factor (TGF)-beta1 stimulates pulmonary fibrosis and inflammation via a Bax-dependent, bid-activated pathway that involves matrix metalloproteinase-12. J. Biol. Chem., 2007, 282, 7723-32.
43. Eickelberg, O.; Kohler, E.; Reichenberger, F.; Bertschin, S.; Woodtli, T.; Erne, P.; Perruchoud, A.P.; Roth, M. Extracellular matrix deposition by primary human lung fibroblasts in response to TGF-beta1 and TGF-beta3. Am. J. Physiol., 1999, 276, L814-24.
44. Klier, C.M.; Nelson, E.L.; Cohen, C.D.; Horuk, R.; Schlondorff, D.; Nelson, P.J. Chemokine-Induced secretion of gelatinase B in primary human monocytes. Biol. Chem., 2001, 382, 1405-10.
45. Van den Steen, P.E.; Proost, P.; Wuyts, A.; Van Damme, J.; Opdenakker, G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood, 2000, 96, 2673-81.
46. Van Den Steen, P.E.; Wuyts, A.; Husson, S.J.; Proost, P.; Van Damme, J.; Opdenakker, G. Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/ LIX and modulate their physiological activities. Eur. J. Biochem., 2003, 270, 3739-49.
47. Corry, D.B.; Rishi, K.; Kanellis, J.; Kiss, A.; Song Lz, L.Z.; Xu, J.; Feng, L.; Werb, Z.; Kheradmand, F. Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency. Nat. Immunol., 2002, 3, 347-53.
48. Prause, O.; Bozinovski, S.; Anderson, G.P.; Linden, A. Increased matrix metalloproteinase-9 concentration and activity after stimulation with interleukin-17 in mouse airways. Thorax, 2004, 59, 313-17.
49. Nelson, K.K.; Melendez, J.A. Mitochondrial redox control of matrix metalloproteinases. Free Radic. Biol. Med., 2004, 37, 768-84.
50. Bracke, K.; Cataldo, D.; Maes, T.; Gueders, M.; Noel, A.; Foidart, J.M.; Brusselle, G.; Pauwels, R.A. Matrix metalloproteinase-12 and cathepsin D expression in pulmonary macrophages and dendritic cells of cigarette smoke-exposed mice. Int. Arch. Allergy Immunol., 2005, 138, 169-79.
51. Su, W.Y.; Jaskot, R.H.; Richards, J.; Abramson, S.R.; Woessner, J.F., Jr.; Yu, W.H.; Dreher, K.L. Induction of pulmonary matrilysin expression by combustion and ambient air particles. Am. J. Physiol. Lung Cell Mol. Physiol., 2000, 279, L152-60.
52. Elkington, P.T.; Emerson, J.E.; Lopez-Pascua, L.D.; O'Kane, C.M.; Horncastle, D.E.; Boyle, J.J.; Friedland, J.S. Mycobacterium tuberculosis up-regulates matrix metalloproteinase-1 secretion from human airway epithelial cells via a p38 MAPK switch. J. Immunol., 2005, 175, 5333-40.
53. Rivera-Marrero, C.A.; Schuyler, W.; Roser, S.; Roman, J. Induction of MMP-9 mediated gelatinolytic activity in human monocytic cells by cell wall components of Mycobacterium tuberculosis. Microb. Pathog., 2000, 29, 231-44.
54. Nagase, H.; Visse, R.; Murphy, G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res., 2006, 69, 562-73.
55. Brew, K.; Dinakarpandian, D.; Nagase, H. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim. Biophys. Acta, 2000, 1477, 267-83.
56. Visse, R.; Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ. Res., 2003, 92, 827-39.
57. Murphy, G.; Houbrechts, A.; Cockett, M.I.; Williamson, R.A.; O'Shea, M.; Docherty, A.J. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry, 1991, 30, 8097-102.
58. Williamson, R.A.; Marston, F.A.; Angal, S.; Koklitis, P.; Panico, M.; Morris, H.R.; Carne, A.F.; Smith, B.J.; Harris, T.J.; Freedman, R.B. Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochem. J., 1990, 268, 267-74.
59. Bond, M.; Murphy, G.; Bennett, M.R.; Newby, A.C.; Baker, A.H. Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J. Biol. Chem., 2002, 277, 13787-95.
60. Ahonen, M.; Poukkula, M.; Baker, A.H.; Kashiwagi, M.; Nagase, H.; Eriksson, J.E.; Kahari, V.M. Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene, 2003, 22, 2121-34.
61. Valente, P.; Fassina, G.; Melchiori, A.; Masiello, L.; Cilli, M.; Vacca, A.; Onisto, M.; Santi, L.; Stetler-Stevenson, W.G.; Albini, A. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int. J. Cancer, 1998, 75, 246-53.
62. Guedez, L.; Courtemanch, L.; Stetler-Stevenson, M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood, 1998, 92, 1342-49.
63. John, A.; Tuszynski, G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol. Oncol. Res., 2001, 7, 14-23.
64. Wagner, S.; Breyholz, H.J.; Faust, A.; Holtke, C.; Levkau, B.; Schober, O.; Schafers, M.; Kopka, K. Molecular imaging of matrix metalloproteinases in vivo using small molecule inhibitors for SPECT and PET. Curr. Med. Chem., 2006, 13, 2819-38.
65. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2002, 2, 161-74.
66. Overall, C.M.; Lopez-Otin, C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer, 2002, 2, 657-72.
67. Sternlicht, M.D.; Lochter, A.; Sympson, C.J.; Huey, B.; Rougier, J.P.; Gray, J.W.; Pinkel, D.; Bissell, M.J.; Werb, Z. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell, 1999, 98, 137-46.
68. Folgueras, A.R.; Pendas, A.M.; Sanchez, L.M.; Lopez-Otin, C. Matrix metalloproteinases in cancer: From new functions to improved inhibition strategies. Int. J. Dev. Biol., 2004, 48, 411-24.
69. Brooks, P.C.; Stromblad, S.; Sanders, L.C.; von Schalscha, T.L.; Aimes, R.T.; Stetler-Stevenson, W.G.; Quigley, J.P.; Cheresh, D.A. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell, 1996, 85, 683-93.
70. Marcus, P.M.; Bergstralh, E.J.; Fagerstrom, R.M.; Williams, D.E.; Fontana, R.; Taylor, W.F.; Prorok, P.C. Lung cancer mortality in the Mayo Lung Project: Impact of extended follow-up. J. Natl. Cancer Inst., 2000, 92, 1308-16.
71. Passlick, B.; Sienel, W.; Seen-Hibler, R.; Wockel, W.; Thetter, O.; Mutschler, W.; Pantel, K. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res., 2000, 6, 3944-48.
72. Kumaki, F.; Matsui, K.; Kawai, T.; Ozeki, Y.; Yu, Z.X.; Ferrans, V.J.; Travis, W.D. Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. Am. J. Pathol., 2001, 159, 2125-35.
73. Herbst, R.S.; Yano, S.; Kuniyasu, H.; Khuri, F.R.; Bucana, C.D.; Guo, F.; Liu, D.; Kemp, B.; Lee, J.J.; Hong, W.K.; Fidler, I.J. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin. Cancer Res., 2000, 6, 790-97.
74. Pan, M.R.; Chuang, L.Y.; Hung, W.C. Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett., 2001, 508, 365-68.
75. Brown, P.D.; Bloxidge, R.E.; Stuart, N.S.; Gatter, K.C.; Carmichael, J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J. Natl. Cancer Inst., 1993, 85, 574-78.
76. Hrabec, E.; Strek, M.; Nowak, D.; Hrabec, Z. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respir. Med., 2001, 95, 1-4.
77. Mao, L.; Yu, S.; Sun, K. An experimental study of matrix metalloproteinase inhibitor BB-94 inhibits the invasion and metastasis of the human salivary adenoid cystic carcinoma in vitro and in vivo. Zhonghua Kou Qiang Yi Xue Za Zhi, 2001, 36, 304-7.
78. Fujise, N.; Nanashim, A.; Taniguchi, Y.; Matsuo, S.; Hatano, K.; Matsumoto, Y.; Tagawa, Y.; Ayabe, H. Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer, 2000, 27, 19-26.
79. Kodate, M.; Kasai, T.; Hashimoto, H.; Yasumoto, K.; Iwata, Y.; Manabe, H. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol. Int., 1997, 47, 461-69.
80. Thomas, P.; Khokha, R.; Shepherd, F.A.; Feld, R.; Tsao, M.S. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J. Pathol., 2000, 190, 150-56.
81. Leinonen, T.; Pirinen, R.; Bohm, J.; Johansson, R.; Ropponen, K.; Kosma, V.M. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis. Lung Cancer, 2006, 51, 313-21.
82. Ylisirnio, S.; Hoyhtya, M.; Turpeenniemi-Hujanen, T. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker. Anticancer Res., 2000, 20, 1311-16.
83. Michael, M.; Babic, B.; Khokha, R.; Tsao, M.; Ho, J.; Pintilie, M.; Leco, K.; Chamberlain, D.; Shepherd, F.A. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J. Clin. Oncol., 1999, 17, 1802-8.
84. Rasmussen, H.S.; McCann, P.P. Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat. Pharmacol. Ther., 1997, 75, 69-75.
85. Denis, L.J.; Verweij, J. Matrix metalloproteinase inhibitors: Present achievements and future prospects. Invest. New Drugs, 1997, 15, 175-85.
86. Scatena, R. Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases. Expert. Opin. Investig. Drugs, 2000, 9, 2159-65.
87. Shepherd, F.A. Angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer, 2001, 34 Suppl 3, S81-9.
88. Zhong, H.; Bowen, J.P. Antiangiogenesis drug design: Multiple pathways targeting tumor vasculature. Curr. Med. Chem., 2006, 13, 849-62.
89. Miserocchi, G. Physiology and pathophysiology of pleural fluid turnover. Eur. Respir. J., 1997, 10, 219-25.
90. Eickelberg, O.; Sommerfeld, C.O.; Wyser, C.; Tamm, M.; Reichenberger, F.; Bardin, P.G.; Soler, M.; Roth, M.; Perruchoud, A.P. MMP and TIMP expression pattern in pleural effusions of different origins. Am. J. Respir. Crit. Care Med., 1997, 156, 1987-92.
91. Philip-Joet, F.; Alessi, M.C.; Philip-Joet, C.; Aillaud, M.; Barriere, J.R.; Arnaud, A.; Juhan-Vague, I. Fibrinolytic and inflammatory processes in pleural effusions. Eur. Respir. J., 1995, 8, 1352-56.
92. Idell, S.; Girard, W.; Koenig, K.B.; McLarty, J.; Fair, D.S. Abnormalities of pathways of fibrin turnover in the human pleural space. Am. Rev. Respir. Dis., 1991, 144, 187-94.
93. Kotyza, J.; Pesek, M.; Puzman, P.; Havel, D. Progelatinase B/matrix metalloproteinase-9 proenzyme as a marker of pleural inflammation. Exp. Lung Res., 2004, 30, 297-309.
94. Marshall, B.C.; Santana, A.; Xu, Q.P.; Petersen, M.J.; Campbell, E.J.; Hoidal, J.R.; Welgus, H.G. Metalloproteinases and tissue inhibitor of metalloproteinases in mesothelial cells. Cellular differentiation influences expression. J. Clin. Invest., 1993, 91, 1792-99.
95. Park, K.J.; Hwang, S.C.; Sheen, S.S.; Oh, Y.J.; Han, J.H.; Lee, K.B. Expression of matrix metalloproteinase-9 in pleural effusions of tuberculosis and lung cancer. Respiration, 2005, 72, 166-75.
96. Zucker, S.; Mirza, H.; Conner, C.E.; Lorenz, A.F.; Drews, M.H.; Bahou, W.F.; Jesty, J. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int. J. Cancer, 1998, 75, 780-86.
97. Hurewitz, A.N.; Wu, C.L.; Mancuso, P.; Zucker, S. Tetracycline and doxycycline inhibit pleural fluid metalloproteinases. A possible mechanism for chemical pleurodesis. Chest, 1993, 103, 1113-17.
98. Di Carlo, A.; Terracciano, D.; Mariano, A.; Macchia, V. Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions. Int. J. Oncol., 2005, 26, 1363-68.
99. Hurewitz, A.N.; Zucker, S.; Mancuso, P.; Wu, C.L.; Dimassimo, B.; Lysik, R.M.; Moutsiakis, D. Human pleural effusions are rich in matrix metalloproteinases. Chest, 1992, 102, 1808-14.
100. Iglesias, D.; Alegre, J.; Aleman, C.; Ruiz, E.; Soriano, T.; Armadans, L.I.; Segura, R.M.; Angles, A.; Monasterio, J.; de Sevilla, T.F. Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions. Eur. Respir. J., 2005, 25, 104-9.
101. Chang, J.C.; Wysocki, A.; Tchou-Wong, K.M.; Moskowitz, N.; Zhang, Y.; Rom, W.N. Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases. Thorax, 1996, 51, 306-11.
102. Quiding-Jarbrink, M.; Smith, D.A.; Bancroft, G.J. Production of matrix metalloproteinases in response to mycobacterial infection. Infect. Immun., 2001, 69, 5661-70.
103. Friedland, J.S.; Shaw, T.C.; Price, N.M.; Dayer, J.M. Differential regulation of MMP-1/9 and TIMP-1 secretion in human monocytic cells in response to Mycobacterium tuberculosis. Matrix Biol., 2002, 21, 103-10.
104. Rivera-Marrero, C.A.; Schuyler, W.; Roser, S.; Ritzenthaler, J.D.; Newburn, S.A.; Roman, J. M. tuberculosis induction of matrix metalloproteinase-9: The role of mannose and receptor-mediated mechanisms. Am. J. Physiol. Lung Cell Mol. Physiol., 2002, 282, L546-55.
105. Hoheisel, G.; Sack, U.; Hui, D.S.; Huse, K.; Chan, K.S.; Chan, K.K.; Hartwig, K.; Schuster, E.; Scholz, G.H.; Schauer, J. Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis. Tuberculosis (Edinb), 2001, 81, 203-9.
106. Jin, H.Y.; Lee, K.S.; Jin, S.M.; Lee, Y.C. Vascular endothelial growth factor correlates with matrix metalloproteinase-9 in the pleural effusion. Respir. Med., 2004, 98, 115-22.
107. Macaulay, V.M.; O'Byrne, K.J.; Saunders, M.P.; Braybrooke, J.P.; Long, L.; Gleeson, F.; Mason, C.S.; Harris, A.L.; Brown, P.; Talbot, D.C. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin. Cancer Res., 1999, 5, 513-20.
108. Landvater, L.; Hix, W.R.; Mills, M.; Siegel, R.S.; Aaron, B.L. Malignant pleural effusion treated by tetracycline sclerotherapy. A comparison of single vs repeated instillation. Chest, 1988, 93, 1196-98.
109. Sherman, S.; Grady, K.J.; Seidman, J.C. Clinical experience with tetracycline pleurodesis of malignant pleural effusions. South Med. J., 1987, 80, 716-19.
110. Gualano, R.C.; Vlahos, R.; Anderson, G.P. What is the contribution of respiratory viruses and lung proteases to airway remodelling in asthma and chronic obstructive pulmonary disease? Pulm. Pharmacol. Ther., 2006, 19, 18-23.
111. Lagente, V.; Manoury, B.; Nenan, S.; Le Quement, C.; Martin-Chouly, C.; Boichot, E. Role of matrix metalloproteinases in the development of airway inflammation and remodeling. Braz. J. Med. Biol. Res., 2005, 38, 1521-30.
112. Pauwels, R. COPD: The scope of the problem in Europe. Chest, 2000, 117, 332S-5S.
113. Barnes, P.J. Genetics and pulmonary medicine. 9. Molecular genetics of chronic obstructive pulmonary disease. Thorax, 1999, 54, 245-52.
114. Barnes, P.J.; Shapiro, S.D.; Pauwels, R.A. Chronic obstructive pulmonary disease: Molecular and cellular mechanisms. Eur. Respir. J., 2003, 22, 672-88.
115. Shapiro, S.D. Proteinases in chronic obstructive pulmonary disease. Biochem. Soc. Trans., 2002, 30, 98-102.
116. Hogg, J.C.; Senior, R.M. Chronic obstructive pulmonary disease - part 2: pathology and biochemistry of emphysema. Thorax, 2002, 57, 830-34.
117. Barnes, P.J. Mechanisms in COPD: Differences from asthma. Chest, 2000, 117, 10S-4S.
118. Sampsonas, F.; Karkoulias, K.; Kaparianos, A.; Spiropoulos, K. Genetics of chronic obstructive pulmonary disease, beyond a1-antitrypsin deficiency. Curr. Med. Chem., 2006, 13, 2857-73.
119. Finlay, G.A.; Russell, K.J.; McMahon, K.J.; D'Arcy E, M.; Masterson, J.B.; FitzGerald, M.X.; O'Connor, C.M. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax, 1997, 52, 502-6.
120. Finlay, G.A.; O'Driscoll, L.R.; Russell, K.J.; D'Arcy, E.M.; Masterson, J.B.; FitzGerald, M.X.; O'Connor, C.M. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am. J. Respir. Crit. Care Med., 1997, 156, 240-47.
121. Ohnishi, K.; Takagi, M.; Kurokawa, Y.; Satomi, S.; Konttinen, Y.T. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab. Invest., 1998, 78, 1077-87.
122. Cataldo, D.; Munaut, C.; Noel, A.; Frankenne, F.; Bartsch, P.; Foidart, J.M.; Louis, R. MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int. Arch. Allergy Immunol., 2000, 123, 259-67.
123. Vignola, A.M.; Riccobono, L.; Mirabella, A.; Profita, M.; Chanez, P.; Bellia, V.; Mautino, G.; D'Accardi, P.; Bousquet, J.; Bonsignore, G. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am. J. Respir. Crit. Care Med., 1998, 158, 1945-50.
124. Demedts, I.K.; Brusselle, G.G.; Bracke, K.R.; Vermaelen, K.Y.; Pauwels, R.A. Matrix metalloproteinases in asthma and COPD. Curr. Opin. Pharmacol., 2005, 5, 257-63.
125. Beeh, K.M.; Beier, J.; Kornmann, O.; Buhl, R. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir. Med., 2003, 97, 634-39.
126. Betsuyaku, T.; Nishimura, M.; Takeyabu, K.; Tanino, M.; Venge, P.; Xu, S.; Kawakami, Y. Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am. J. Respir. Crit. Care Med., 1999, 159, 1985-91.
127. Shapiro, S.D.; Kobayashi, D.K.; Ley, T.J. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J. Biol. Chem., 1993, 268, 23824-29.
128. Molet, S.; Belleguic, C.; Lena, H.; Germain, N.; Bertrand, C.P.; Shapiro, S.D.; Planquois, J.M.; Delaval, P.; Lagente, V. Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease. Inflamm. Res., 2005, 54, 31-6.
129. Lavigne, M.C.; Thakker, P.; Gunn, J.; Wong, A.; Miyashiro, J.S.; Wasserman, A.M.; Wei, S.Q.; Pelker, J.W.; Kobayashi, M.; Eppihimer, M.J. Human bronchial epithelial cells express and secrete MMP-12. Biochem. Biophys. Res. Commun., 2004, 324, 534-46.
130. Lavigne, M.C.; Eppihimer, M.J. Cigarette smoke condensate induces MMP-12 gene expression in airway-like epithelia. Biochem. Biophys. Res. Commun., 2005, 330, 194-203.
131. Le Naour, F.; Hohenkirk, L.; Grolleau, A.; Misek, D.E.; Lescure, P.; Geiger, J.D.; Hanash, S.; Beretta, L. Profiling changes in gene expression during differentiation and maturation of monocyte-derived dendritic cells using both oligonucleotide microarrays and proteomics. J. Biol. Chem., 2001, 276, 17920-31.
132. Hautamaki, R.D.; Kobayashi, D.K.; Senior, R.M.; Shapiro, S.D. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science, 1997, 277, 2002-4.
133. Montano, M.; Beccerril, C.; Ruiz, V.; Ramos, C.; Sansores, R.H.; Gonzalez-Avila, G. Matrix metalloproteinases activity in COPD associated with wood smoke. Chest, 2004, 125, 466-72.
134. Demedts, I.K.; Morel-Montero, A.; Lebecque, S.; Pacheco, Y.; Cataldo, D.; Joos, G.F.; Pauwels, R.A.; Brusselle, G.G. Elevated MMP-12 protein levels in induced sputum from patients with COPD. Thorax, 2006, 61, 196-201.
135. Matsumoto, K.; Saito, H. The role of eosinophils in asthma: Sarastro or the Queen of the Night? Int. Arch. Allergy Immunol., 2001, 125, 290-96.
136. Gueders, M.M.; Balbin, M.; Rocks, N.; Foidart, J.M.; Gosset, P.; Louis, R.; Shapiro, S.; Lopez-Otin, C.; Noel, A.; Cataldo, D.D. Matrix metalloproteinase-8 deficiency promotes granulocytic allergen-induced airway inflammation. J. Immunol., 2005, 175, 2589-97.
137. Barnes, P.J.; Chung, K.F.; Page, C.P. Inflammatory mediators of asthma: an update. Pharmacol. Rev., 1998, 50, 515-96.
138. Levine, S.J. Bronchial epithelial cell-cytokine interactions in airway inflammation. J. Investig. Med., 1995, 43, 241-49.
139. Saunders, M.A.; Mitchell, J.A.; Seldon, P.M.; Yacoub, M.H.; Barnes, P.J.; Giembycz, M.A.; Belvisi, M.G. Release of granulocyte-macrophage colony stimulating factor by human cultured airway smooth muscle cells: suppression by dexamethasone. Br. J. Pharmacol., 1997, 120, 545-46.
140. John, M.; Hirst, S.J.; Jose, P.J.; Robichaud, A.; Berkman, N.; Witt, C.; Twort, C.H.; Barnes, P.J.; Chung, K.F. Human airway smooth muscle cells express and release RANTES in response to T helper 1 cytokines: regulation by T helper 2 cytokines and corticosteroids. J. Immunol., 1997, 158, 1841-47.
141. Elshaw, S.R.; Henderson, N.; Knox, A.J.; Watson, S.A.; Buttle, D.J.; Johnson, S.R. Matrix metalloproteinase expression and activity in human airway smooth muscle cells. Br. J. Pharmacol., 2004, 142, 1318-24.
142. Dunsmore, S.E.; Saarialho-Kere, U.K.; Roby, J.D.; Wilson, C.L.; Matrisian, L.M.; Welgus, H.G.; Parks, W.C. Matrilysin expression and function in airway epithelium. J. Clin. Invest., 1998, 102, 1321-31.
143. Dahlen, B.; Shute, J.; Howarth, P. Immunohistochemical localisation of the matrix metalloproteinases MMP-3 and MMP-9 within the airways in asthma. Thorax, 1999, 54, 590-96.
144. Mautino, G.; Henriquet, C.; Jaffuel, D.; Bousquet, J.; Capony, F. Tissue inhibitor of metalloproteinase-1 levels in bronchoalveolar lavage fluid from asthmatic subjects. Am. J. Respir. Crit. Care Med., 1999, 160, 324-30.
145. Cataldo, D.D.; Gueders, M.; Munaut, C.; Rocks, N.; Bartsch, P.; Foidart, J.M.; Noel, A.; Louis, R. Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases mRNA transcripts in the bronchial secretions of asthmatics. Lab. Invest., 2004, 84, 418-24.
146. Ohno, I.; Ohtani, H.; Nitta, Y.; Suzuki, J.; Hoshi, H.; Honma, M.; Isoyama, S.; Tanno, Y.; Tamura, G.; Yamauchi, K.; Nagura, H.; Shirato, K. Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am. J. Respir. Cell Mol. Biol., 1997, 16, 212-19.
147. Mautino, G.; Oliver, N.; Chanez, P.; Bousquet, J.; Capony, F. Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. Am. J. Respir. Cell Mol. Biol., 1997, 17, 583-91.
148. Bosse, M.; Chakir, J.; Rouabhia, M.; Boulet, L.P.; Audette, M.; Laviolette, M. Serum matrix metalloproteinase-9:TIssue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. Am. J. Respir. Crit. Care Med., 1999, 159, 596-602.
149. Simpson, J.L.; Scott, R.J.; Boyle, M.J.; Gibson, P.G. Differential proteolytic enzyme activity in eosinophilic and neutrophilic asthma. Am. J. Respir. Crit. Care Med., 2005, 172, 559-65.
150. Mattos, W.; Lim, S.; Russell, R.; Jatakanon, A.; Chung, K.F.; Barnes, P.J. Matrix metalloproteinase-9 expression in asthma: Effect of asthma severity, allergen challenge, and inhaled corticosteroids. Chest, 2002, 122, 1543-52.
151. Yao, P.M.; Maitre, B.; Delacourt, C.; Buhler, J.M.; Harf, A.; Lafuma, C. Divergent regulation of 92-kDa gelatinase and TIMP-1 by HBECs in response to IL-1beta and TNF-alpha. Am. J. Physiol., 1997, 273, L866-74.
152. Johnatty, R.N.; Taub, D.D.; Reeder, S.P.; Turcovski-Corrales, S.M.; Cottam, D.W.; Stephenson, T.J.; Rees, R.C. Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J. Immunol., 1997, 158, 2327-33.
153. Okada, S.; Kita, H.; George, T.J.; Gleich, G.J.; Leiferman, K.M. Migration of eosinophils through basement membrane components in vitro: Role of matrix metalloproteinase-9. Am. J. Respir. Cell Mol. Biol., 1997, 17, 519-28.
154. Delclaux, C.; Delacourt, C.; D'Ortho, M.P.; Boyer, V.; Lafuma, C.; Harf, A. Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am. J. Respir. Cell Mol. Biol., 1996, 14, 288-95.
155. Saren, P.; Welgus, H.G.; Kovanen, P.T. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J. Immunol., 1996, 157, 4159-65.
156. Corcoran, M.L.; Stetler-Stevenson, W.G.; Brown, P.D.; Wahl, L.M. Interleukin 4 inhibition of prostaglandin E2 synthesis blocks interstitial collagenase and 92-kDa type IV collagenase/gelatinase production by human monocytes. J. Biol. Chem., 1992, 267, 515-19.
157. Mertz, P.M.; DeWitt, D.L.; Stetler-Stevenson, W.G.; Wahl, L.M. Interleukin 10 suppression of monocyte prostaglandin H synthase-2. Mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production. J. Biol. Chem., 1994, 269, 21322-29.
158. Cataldo, D.; Munaut, C.; Noel, A.; Frankenne, F.; Bartsch, P.; Foidart, J.M.; Louis, R. Matrix metalloproteinases and TIMP-1 production by peripheral blood granulocytes from COPD patients and asthmatics. Allergy, 2001, 56, 145-51.
159. Prikk, K.; Maisi, P.; Pirila, E.; Reintam, M.A.; Salo, T.; Sorsa, T.; Sepper, R. Airway obstruction correlates with collagenase-2 (MMP-8) expression and activation in bronchial asthma. Lab. Invest., 2002, 82, 1535-45.
160. Lanone, S.; Zheng, T.; Zhu, Z.; Liu, W.; Lee, C.G.; Ma, B.; Chen, Q.; Homer, R.J.; Wang, J.; Rabach, L.A.; Rabach, M.E.; Shipley, J.M.; Shapiro, S.D.; Senior, R.M.; Elias, J.A. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling. J. Clin. Invest., 2002, 110, 463-74.
161. Chiba, Y.; Yu, Y.; Sakai, H.; Misawa, M. Increase in the expression of matrix metalloproteinase-12 in the airways of rats with allergic bronchial asthma. Biol. Pharm. Bull., 2007, 30, 318-23.
162. Xie, S.; Issa, R.; Sukkar, M.B.; Oltmanns, U.; Bhavsar, P.K.; Papi, A.; Caramori, G.; Adcock, I.; Chung, K.F. Induction and regulation of matrix metalloproteinase-12 in human airway smooth muscle cells. Respir. Res., 2005, 6, 148.
163. Jeffery, P.K. Comparative morphology of the airways in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 1994, 150, S6-13.
164. Rajah, R.; Nachajon, R.V.; Collins, M.H.; Hakonarson, H.; Grunstein, M.M.; Cohen, P. Elevated levels of the IGF-binding protein protease MMP-1 in asthmatic airway smooth muscle. Am. J. Respir. Cell Mol. Biol., 1999, 20, 199-208.
165. Hoshino, M.; Takahashi, M.; Takai, Y.; Sim, J. Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J. Allergy Clin. Immunol., 1999, 104, 356-63.
166. Nieman, G.F.; Zerler, B.R. A role for the anti-inflammatory properties of tetracyclines in the prevention of acute lung injury. Curr. Med. Chem., 2001, 8, 317-25.
167. Atabai, K.; Matthay, M.A. The pulmonary physician in critical care. 5: Acute lung injury and the acute respiratory distress syndrome: definitions and epidemiology. Thorax, 2002, 57, 452-58.
168. Matthay, M.A.; Zimmerman, G.A. Acute lung injury and the acute respiratory distress syndrome: Four decades of inquiry into pathogenesis and rational management. Am. J. Respir. Cell Mol. Biol., 2005, 33, 319-27.
169. Bellingan, G.J. The pulmonary physician in critical care * 6: The pathogenesis of ALI/ARDS. Thorax, 2002, 57, 540-46.
170. Puneet, P.; Moochhala, S.; Bhatia, M. Chemokines in acute respiratory distress syndrome. Am. J. Physiol. Lung Cell Mol. Physiol., 2005, 288, L3-15.
171. Corbel, M.; Boichot, E.; Lagente, V. Role of gelatinases MMP-2 and MMP-9 in tissue remodeling following acute lung injury. Braz. J. Med. Biol. Res., 2000, 33, 749-54.
172. Warner, R.L.; Beltran, L.; Younkin, E.M.; Lewis, C.S.; Weiss, S.J.; Varani, J.; Johnson, K.J. Role of stromelysin 1 and gelatinase B in experimental acute lung injury. Am. J. Respir. Cell Mol. Biol., 2001, 24, 537-44.
173. Mulligan, M.S.; Desrochers, P.E.; Chinnaiyan, A.M.; Gibbs, D.F.; Varani, J.; Johnson, K.J.; Weiss, S.J. In vivo suppression of immune complex-induced alveolitis by secretory leukoproteinase inhibitor and tissue inhibitor of metalloproteinases 2. Proc. Natl. Acad. Sci. USA, 1993, 90, 11523-27.
174. Kleeberger, S.R.; Bassett, D.J.; Jakab, G.J.; Levitt, R.C. A genetic model for evaluation of susceptibility to ozone-induced inflammation. Am. J. Physiol., 1990, 258, L313-20.
175. D'Ortho, M.P.; Jarreau, P.H.; Delacourt, C.; Macquin-Mavier, I.; Levame, M.; Pezet, S.; Harf, A.; Lafuma, C. Matrix metalloproteinase and elastase activities in LPS-induced acute lung injury in guinea pigs. Am. J. Physiol., 1994, 266, L209-16.
176. Pardo, A.; Selman, M.; Ridge, K.; Barrios, R.; Sznajder, J.I. Increased expression of gelatinases and collagenase in rat lungs exposed to 100% oxygen. Am. J. Respir. Crit. Care Med., 1996, 154, 1067-75.
177. Fligiel, S.E.; Standiford, T.; Fligiel, H.M.; Tashkin, D.; Strieter, R.M.; Warner, R.L.; Johnson, K.J.; Varani, J. Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury. Hum. Pathol., 2006, 37, 422-30.
178. Ricou, B.; Nicod, L.; Lacraz, S.; Welgus, H.G.; Suter, P.M.; Dayer, J.M. Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med., 1996, 154, 346-52.
179. Sweet, D.G.; McMahon, K.J.; Curley, A.E.; O'Connor, C.M.; Halliday, H.L. Type I collagenases in bronchoalveolar lavage fluid from preterm babies at risk of developing chronic lung disease. Arch. Dis. Child Fetal Neonatal Ed., 2001, 84, F168-71.
180. Cederqvist, K.; Sorsa, T.; Tervahartiala, T.; Maisi, P.; Reunanen, K.; Lassus, P.; Andersson, S. Matrix metalloproteinases-2, -8, and -9 and TIMP-2 in tracheal aspirates from preterm infants with respiratory distress. Pediatrics, 2001, 108, 686-92.
181. Hartog, C.M.; Wermelt, J.A.; Sommerfeld, C.O.; Eichler, W.; Dalhoff, K.; Braun, J. Pulmonary matrix metalloproteinase excess in hospital-acquired pneumonia. Am. J. Respir. Crit. Care Med., 2003, 167, 593-98.
182. Lanchou, J.; Corbel, M.; Tanguy, M.; Germain, N.; Boichot, E.; Theret, N.; Clement, B.; Lagente, V.; Malledant, Y. Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients. Crit. Care Med., 2003, 31, 536-42.
183. Shapiro, S.D. Matrix metalloproteinase degradation of extracellular matrix: Biological consequences. Curr. Opin. Cell Biol., 1998, 10, 602-8.
184. Atkinson, J.J.; Senior, R.M. Matrix metalloproteinase-9 in lung remodeling. Am. J. Respir. Cell Mol. Biol., 2003, 28, 12-24.
185. Gibbs, D.F.; Shanley, T.P.; Warner, R.L.; Murphy, H.S.; Varani, J.; Johnson, K.J. Role of matrix metalloproteinases in models of macrophage-dependent acute lung injury. Evidence for alveolar macrophage as source of proteinases. Am. J. Respir. Cell Mol. Biol., 1999, 20, 1145-54.
186. Warner, R.L.; Bhagavathula, N.; Nerusu, K.C.; Lateef, H.; Younkin, E.; Johnson, K.J.; Varani, J. Matrix metalloproteinases in acute inflammation: Induction of MMP-3 and MMP-9 in fibroblasts and epithelial cells following exposure to pro-inflammatory mediators in vitro. Exp. Mol. Pathol., 2004, 76, 189-95.
187. King, T.E., Jr. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am. J. Respir. Crit. Care Med., 2005, 172, 268-79.
188. Razzaque, M.S.; Taguchi, T. Pulmonary fibrosis: Cellular and molecular events. Pathol. Int., 2003, 53, 133-45.
189. Agostini, C.; Gurrieri, C. Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc., 2006, 3, 357-63.
190. Selman, M.; Pardo, A. Role of epithelial cells in idiopathic pulmonary fibrosis: From innocent targets to serial killers. Proc. Am. Thorac. Soc., 2006, 3, 364-72.
191. Selman, M.; King, T.E.; Pardo, A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med., 2001, 134, 136-51.
192. Pardo, A.; Selman, M. Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc. Am. Thorac. Soc., 2006, 3, 383-88.
193. Zuo, F.; Kaminski, N.; Eugui, E.; Allard, J.; Yakhini, Z.; Ben-Dor, A.; Lollini, L.; Morris, D.; Kim, Y.; DeLustro, B.; Sheppard, D.; Pardo, A.; Selman, M.; Heller, R.A. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc. Natl. Acad. Sci. USA, 2002, 99, 6292-97.
194. Selman, M.; Pardo, A.; Barrera, L.; Estrada, A.; Watson, S.R.; Wilson, K.; Aziz, N.; Kaminski, N.; Zlotnik, A. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med., 2006, 173, 188-98.
195. Fukuda, Y.; Ishizaki, M.; Kudoh, S.; Kitaichi, M.; Yamanaka, N. Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Lab. Invest., 1998, 78, 687-98.
196. Lemjabbar, H.; Gosset, P.; Lechapt-Zalcman, E.; Franco-Montoya, M.L.; Wallaert, B.; Harf, A.; Lafuma, C. Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis: effects of steroid and immunosuppressive treatment. Am. J. Respir. Cell Mol. Biol., 1999, 20, 903-13.
197. Winkler, M.K.; Fowlkes, J.L. Metalloproteinase and growth factor interactions: Do they play a role in pulmonary fibrosis? Am. J. Physiol. Lung Cell Mol. Physiol., 2002, 283, L1-11.
198. Selman, M.; Ruiz, V.; Cabrera, S.; Segura, L.; Ramirez, R.; Barrios, R.; Pardo, A. TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am. J. Physiol. Lung Cell Mol. Physiol., 2000, 279, L562-74.
199. Chakrabarti, S.; Patel, K.D. Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology. Exp. Lung Res., 2005, 31, 599-621.
200. Ramos, C.; Montano, M.; Garcia-Alvarez, J.; Ruiz, V.; Uhal, B.D.; Selman, M.; Pardo, A. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am. J. Respir. Cell Mol. Biol., 2001, 24, 591-98.
201. Fernandez Fabrellas, E. [Epidemiology of sarcoidosis]. Arch. Bronconeumol., 2007, 43, 92-100.
202. Muller-Quernheim, J. Sarcoidosis: Immunopathogenetic concepts and their clinical application. Eur. Respir. J., 1998, 12, 716-38.
203. John, M.; Oltmanns, U.; Fietze, I.; Witt, C.; Jung, K. Increased production of matrix metalloproteinase-2 in alveolar macrophages and regulation by interleukin-10 in patients with acute pulmonary sarcoidosis. Exp. Lung Res., 2002, 28, 55-68.
204. Ziegenhagen, M.W.; Schrum, S.; Zissel, G.; Zipfel, P.F.; Schlaak, M.; Muller-Quernheim, J. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J. Investig. Med., 1998, 46, 223-31.
205. Fireman, E.; Kraiem, Z.; Sade, O.; Greif, J.; Fireman, Z. Induced sputum-retrieved matrix metalloproteinase 9 and tissue metalloproteinase inhibitor 1 in granulomatous diseases. Clin. Exp. Immunol., 2002, 130, 331-37.
206. Fireman, E.M.; Topilsky, M.R. Sarcoidosis: An organized pattern of reaction from immunology to therapy. Immunol. Today, 1994, 15, 199-201.
207. Newman, L.S.; Rose, C.S.; Maier, L.A. Sarcoidosis. N. Engl. J. Med., 1997, 336, 1224-34.
208. Henry, M.T.; McMahon, K.; Mackarel, A.J.; Prikk, K.; Sorsa, T.; Maisi, P.; Sepper, R.; Fitzgerald, M.X.; O'Connor, C.M. Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF. Eur. Respir. J., 2002, 20, 1220-27.
209. Gonzalez, A.A.; Segura, A.M.; Horiba, K.; Qian, S.; Yu, Z.X.; Stetler-Stevenson, W.; Willerson, J.T.; McAllister, H.A., Jr.; Ferrans, V.J. Matrix metalloproteinases and their tissue inhibitors in the lesions of cardiac and pulmonary sarcoidosis: An immunohistochemical study. Hum. Pathol., 2002, 33, 1158-64.